AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10593710
Drug: Reference administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference administered as loose (separate) formulations
Trial: 8618186
Drug: Subcutaneous Epo
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous Epo (200 units/kg per day for 10 days)
Trial: 8618186
Drug: Epo in
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epo in TPN solution (200 units/kg per day for 10 days)
Trial: 8618186
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (subcutaneous and TPN)
Trial: 7100224
Drug: Cefuroxime 750
RxNorm normalized name: cefuroxime 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefuroxime 750 mg intravenously before and every 8 hours for the first 72 hours post-operatively
Trial: 31634729
Drug: Standard antiepileptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiepileptic drugs (AEDs)
Trial: 29217600
Drug: Extra-fine beclometasone/formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-fine beclometasone/formoterol maintenance and reliever therapy (MART)
Trial: 24423311
Drug: GIP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GIP infusion (2 pmol × kg(‐1) × min(‐1))
Trial: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.2%) alone, 0.7 ml/kg (Group R)
Trial: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.2%) plus tramadol (2 mg/kg), total volume 0.7 ml/kg (Group RT)
Trial: 20665055
Drug: Ropivacaine (0.2%)
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine (0.2%) plus tramadol (2 mg/kg) (Group RT)
Trial: 15201783
Drug: Intravesical resiniferatoxin
RxNorm normalized name: Valrubicin Intravesical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical resiniferatoxin (0.6 microM in 50 ml of 0.9% NaCl)
Trial: 15201783
Drug: Botulinum-A toxin
RxNorm normalized name: Botulinum A neurotoxin
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum-A toxin injections (300 units diluted in 30 ml 0.9% NaCl)
Trial: 9792371
Drug: 3TC (lamivudine)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3TC (lamivudine) syrup or tablets (4 mg/kg twice daily)
Trial: 3683021
Drug: Indomethacin 50
RxNorm normalized name: indomethacin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 50 mg
Trial: 2655691
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Ibuprofen and Indomethacin)
Trial: 31195902
Drug: Tamoxifen treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen treatment only (Control)
Trial: 26048780
Drug: H4:IC31 (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H4:IC31 (5, 15, 50, or 150 μg with 500nmol IC31)
Trial: 16449816
Drug: Cetirizine and
RxNorm normalized name: Cetirizine and pseudoephedrine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine and theophylline (200 mg twice daily)
Trial: 9265948
Drug: Mirtazapine (5-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirtazapine (5-35 mg/day)
Trial: 9265948
Drug: Amitriptyline (40-280
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (40-280 mg/day)
Trial: 22519919
Drug: Imeglimin 1000
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Imeglimin 1000 mg twice daily
Trial: 30636830
Drug: Oxaceprol 200
RxNorm normalized name: oxaceprol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxaceprol 200 mg thrice daily
Trial: 30636830
Drug: Tramadol 50
RxNorm normalized name: traMADol 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 50 mg thrice daily
Trial: 26437063
Drug: Cyclosporine (CSA)
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (CSA) with target blood concentration of 500 ng/ml
Trial: 26437063
Drug: Tacrolimus (TAC)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus (TAC) with target blood concentration of 15 ng/ml
Trial: 14563464
Drug: Thiocolchicoside (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiocolchicoside (4 mg-2 ml) administered twice daily for 5 days
Trial: 7633976
Drug: Fibrin sealant
RxNorm normalized name: FIBRIN SEALANT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrin sealant as a topical haemostatic agent
Trial: 6401753
Drug: Nifedipine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (20 mg, by mouth)
Trial: 29092885
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (42 mg elemental Fe/d)
Trial: 30413211
Drug: Biological implants
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological implants (Permacol™, Medtronic)
Trial: 27054679
Drug: Three combat
RxNorm normalized name: Provita Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three combat rations plus four 250-kcal protein-based bars (PRO, 20 g protein)
Trial: 27054679
Drug: Three combat
RxNorm normalized name: Provita Combat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three combat rations plus four 250-kcal carbohydrate-based bars (CHO, 48 g carbohydrate)
Trial: 19889062
Drug: Fesoterodine 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 12 mg
Trial: 18044291
Drug: ketamine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketamine 0.4 mg/kg
Trial: 18044291
Drug: thiopental 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiopental 0.5 mg/kg
Trial: 18044291
Drug: meperidine 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: meperidine 0.5 mg/kg
Trial: 18044291
Drug: lidocaine 1
RxNorm normalized name: lidocaine 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lidocaine 1 mg/kg
Trial: 20394247
Drug: saline 3
RxNorm normalized name: CVS Saline 3.0% Nasal Mist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline 3 ml
Trial: 12105362
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg/d
Trial: 10394155
Drug: Endovascular graft
RxNorm normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endovascular graft (EVG) treatment (22 patients, 14 bifurcated, 8 tube)
Trial: 7590615
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose load (0.75 g/kg BW per os, OGTT)
Trial: 7590615
Drug: Intravenous glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucose bolus (25 g i.v., IVGTT)
Trial: 29510649
Drug: Letrozole (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (5 mg)
Trial: 30184105
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) (100 mg)
Trial: 29955768
Drug: pegcantratinib, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegcantratinib, 0.5% (wt/wt), applied once daily for 12 weeks
Trial: 29955768
Drug: placebo, applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, applied once daily for 12 weeks
Trial: 29955768
Drug: pegcantratinib, 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegcantratinib, 0.5% (wt/wt), applied once daily for 4 weeks (phase 1b)
Trial: 19155372
Drug: Semisynthetic penicillins
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Semisynthetic penicillins (SSPs) including amoxicillin, ampicillin, pivampicillin
Trial: 17448413
Drug: Spironolactone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (20 mg daily)
Trial: 11555062
Drug: Oseltamivir 75
RxNorm normalized name: oseltamivir 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oseltamivir 75 mg once daily for 6 weeks
Trial: 28160494
Drug: Midazolam 5
RxNorm normalized name: midazolam 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 5 mg - Droperidol 5 mg
Trial: 465271
Drug: Droperidol 10
RxNorm normalized name: droperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 10 mg
Trial: 23303067
Drug: Craving in
RxNorm normalized name: BENZALKONIUM CHLORIDE 13 mg in 1 mL TOPICAL SPRAY [Skin Crave non-alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Craving in the week before treatment
Trial: 21499196
Drug: Glutamine-enriched total
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-enriched total parenteral nutrition (GE-TPN) solution consisting of 0.4 g/kg/day of l-alanine-glutamine dipeptide
Trial: 21499196
Drug: Standard total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard total parenteral nutrition (S-TPN)
Trial: 21499196
Drug: Glutamine-enriched total
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine-enriched total parenteral nutrition (GE-TPN) solution
Trial: 18000176
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day pioglitazone for 16 weeks
Trial: 9989513
Drug: Pion radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pion radiation therapy
Trial: 9989513
Drug: Conventional external
RxNorm normalized name: CATHETER,EXTERNAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional external beam photon therapy
Trial: 7590426
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (350 ml)
Trial: 7590426
Drug: Low calorie
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low calorie orange cordial (50 ml)
Trial: 449951
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B and flucytosine combination therapy
Trial: 31661438
Drug: Composite mesh
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Composite mesh (Ventralex Patch)
Trial: 28260702
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg) twice daily
Trial: 28260702
Drug: Sitagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (50 mg) once daily
Trial: 15193811
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroxine (T4) therapy
Trial: 11208941
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of oral Lipiodol
Trial: 2736096
Drug: topical fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical fluorouracil
Trial: 31116102
Drug: Behavioral therapy
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral therapy with diaphragmatic breathing and biofeedback therapy
Trial: 31116102
Drug: Baclofen at
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Baclofen at a dose of 10 mg three times daily
Trial: 28179221
Drug: Daily sugar-sweetened
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily sugar-sweetened beverage consumption
Trial: 23458405
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (300 mg/day for 40 days)
Trial: 30814417
Drug: Curcumin ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin ingestion (180 mg/d) 4 d after exercise (POST)
Trial: 30814417
Drug: Curcumin ingestion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin ingestion (180 mg/d) 7 d before exercise (PRE)
Trial: 30814417
Drug: Placebo (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (180 mg/d) 4 d after exercise (CON)
Trial: 21205939
Drug: Intraarterial administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial administration of BM‐MNC
Trial: 21205939
Drug: Repeated BM‐MNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated BM‐MNC administration
Trial: 21205939
Drug: Ulcer healing
RxNorm normalized name: Ulcer healing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulcer healing induced by repeated BM‐MNC administration
Trial: 15327525
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose coumadin (1 mg/d)
Trial: 15327525
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH, enoxaparin 40 mg s.c. q.d.)
Trial: 15327525
Drug: Thalidomide and
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thalidomide and chemotherapy during consolidation treatment
Trial: 9052314
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg cisatracurium
Trial: 9052314
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg cisatracurium
Trial: 2576216
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg vecuronium
Trial: 8134772
Drug: Five doses
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five doses of ivermectin
Trial: 8134772
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of ivermectin
Trial: 3526522
Drug: TL-102 (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL-102 (beclomethasone dipropionate powder preparation) 50 micrograms with 30 micrograms of hydroxypropylcellulose, administered intranasally at a dose of 2 capsules/day b.i.d. for one week
Trial: 3526522
Drug: TL-102 (beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TL-102 (beclomethasone dipropionate powder preparation)
Trial: 3526522
Drug: Conventional BDP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional BDP preparations
Trial: 27055601
Drug: Relamorelin 10
RxNorm normalized name: Relamorelin
DrugBank: Relamorelin (DB12678)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relamorelin 10 μg twice daily
Trial: 25027701
Drug: Thiamin supplementation
RxNorm normalized name: thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiamin supplementation (10 mg/day for 7 days, then 5 mg daily until day 42)
Trial: 20187947
Drug: Early medication
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early medication change (EMC) strategy
Trial: 16307968
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (Leuprorelin 3.75 mg/28 days)
Trial: 16307968
Drug: Subdermal progestin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subdermal progestin implant (etonogestrel 68 mg)
Trial: 10714913
Drug: Calcium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium alone (750 mg)
Trial: 11193131
Drug: CEE 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.3 mg
Trial: 11591613
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg
Trial: 26405233
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of autologous bone marrow-derived cells (BMC)
Trial: 25350669
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D 50,000 IU once a week for 2 months and then monthly for 10 months
Trial: 22406101
Drug: Supportive Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supportive Therapy (Control)
Trial: 7959187
Drug: Gelatin capsules
RxNorm normalized name: Gelatin Capsules
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules
Trial: 18794541
Drug: Chemotherapy (CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT arm; fluorouracil [FU] 400 mg/m(2) IV once daily plus dl‐leucovorin 200 mg/m(2) for 5 days or FU 370 mg/m(2) plus l‐leucovorin 100 mg/m(2) IV for 5 days for six cycles at 28-day intervals)
Trial: 18794541
Drug: Chemotherapy (CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (CT arm)
Trial: 9683312
Drug: Controlled onset-extended
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Oncet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled onset-extended release (COER)-verapamil (180 mg/d)
Trial: 7655108
Drug: Calcipotriol in
RxNorm normalized name: Product containing calcipotriol in cutaneous dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol in ointment for 12 weeks
Trial: 7655108
Drug: Ointment base
RxNorm normalized name: Ointment base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ointment base only for 12 weeks
Trial: 30341006
Drug: Cligosiban 0.3-2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 0.3-2,400 mg (aqueous solutions or dispersions)
Trial: 30341006
Drug: Cligosiban 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 800 mg (capsules and aqueous dispersion)
Trial: 30341006
Drug: Cligosiban 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban 1,600 mg (caplets and aqueous dispersion)
Trial: 30341006
Drug: Cligosiban (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban (various doses)
Trial: 30341006
Drug: Cligosiban (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cligosiban (800 mg)
Trial: 19455053
Drug: High-dose CP-532,623
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CP-532,623
Trial: 19455053
Drug: Low-dose CP-532,623
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose CP-532,623
Trial: 11379808
Drug: HFA-BDP (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HFA-BDP (200 to 800 microg daily)
Trial: 11379808
Drug: CFC-BDP (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CFC-BDP (400 to 1600 microg daily)
Trial: 11072419
Drug: Caffeine 400
RxNorm normalized name: caffeine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 400 mg
Trial: 3222359
Drug: Caffeine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (200 mg and 400 mg)
Trial: 27051055
Drug: Interval cytoreductive
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval cytoreductive surgery (CS) with hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatin (50 mg/m2) for 60 minutes after complete cytoreduction.
Trial: 27051055
Drug: Standard first-line
RxNorm normalized name: Standard ANSI First Aid KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard first-line treatment (6 conventional cycles of chemotherapy after CS with HIPEC).
Trial: 22614720
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee with 67 mg caffeine
Trial: 22614720
Drug: Decaffeinated coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated coffee with 134 mg caffeine
Trial: 21879101
Drug: Regular coffee
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular coffee (130 mg caffeine)
Trial: 21879101
Drug: Placebo-control capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo-control capsule
Trial: 15025848
Drug: Liquid formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid formulation of r-hCG (0.5 mL of 250 microg/0.5 mL)
Trial: 15025848
Drug: Freeze-dried formulation
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried formulation of r-hCG (1.0 mL of 250 microg/mL)
Trial: 10990077
Drug: Oral insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral insulin (5 mg daily)
Trial: 3966831
Drug: Vitamin K
RxNorm normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K treatment
Trial: 27783849
Drug: Peptide cocktail
RxNorm normalized name: Multipeptide cocktail
DrugBank: CoVac-1 (DB16429)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide cocktail therapy (KIF20A-derived peptide vaccine combined with antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2) plus gemcitabine
Trial: 12899793
Drug: rhIFN-gamma (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhIFN-gamma (1 MU intramuscularly daily for the first three months and 1 MU every other day for the following six months)
Trial: 12730746
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg risedronate